FDA 510(k) Aggregate Change Analysis for Special 510(k)-Cleared Devices

A Special 510(k) is intrinsically by definition a 510(k) intended to detail only a 510(k)-cleared device modification(s) rather than to detail the 510(k)-cleared aspects that haven’t been modified.  This means that the subject device described in the Special 510(k) cannot be fully characterized and understood simply by what is stated directly in the Special 510(k) document submission.  Indeed, FDA itself says that [see the Special 510(k) guidance], in order to have a complete understanding of the device under review, the Special 510(k) is to a) detail the change(s) made that triggered the Special 510(k), and then also b) regarding the aspects that weren’t changed, “…state that no changes were made“.

So a properly written Special 510(k) will simply make such a generic statement for whatever 510(k)-cleared aspects haven’t been changed.  In other words, those unchanged aspects are “incorporated by reference”, and thus aren’t actually described directly in the Special 510(k) submission.  But this certainly does not mean that those unchanged 510(k)-cleared aspects are no longer part of the device’s current 510(k) clearance.  They are definitely there, specifically by way of their incorporation by reference into the Special 510(k).  Therefore, to fully understand those 510(k)-cleared attributes, one is forced to go to the 510(k) submission document where they were detailed.

Ultimately, it is in contravention of U.S. medical device law to assert that those unchanged 510(k)-cleared aspects are somehow nullified by their generic incorporation by reference into the Special 510(k).  Again, a Special 510(k) is intrinsically for detailing modifications that are to be paired with the various unchanged 510(k)-cleared aspects so as to represent the full 510(k)-cleared version.

FDA 510(k) Modifications – Inclusion of Non-Triggering Change Details

If multiple changes have been made to the subject device since the prior 510(k), but where only one/some of those changes trigger(s) the need for a new 510(k), and if the aggregate of changes isn’t what’s triggering the need for the new 510(k), then you “should” (meaning this isn’t a requirement) in the 510(k) simply identify and describe the nature of the changes that don’t require submission of the new 510(k).   Indeed, the actual mandate regarding the non-triggering changes is for you to detail those aspects internally in accordance with the QS regulations.  In other words, the developmental documentation and data (e.g., test results/reports, etc.) associated with the non-triggering aspects should definitely NOT be included in the 510(k).  Instead, keep the substance of the 510(k) focused on those aspects that triggered the 510(k) for the changed device; specifically, those changes that can “significantly affect safety and effectiveness”.  I explain further below.

A 510(k) is a statutory creature that has a very specific purpose; namely, to demonstrate the statutory substantial equivalence of the subject device in comparison to a predicate device.  Accordingly, I generally advise and practice that the substance of the 510(k) needs to be strictly and succinctly focused on that statutory substantial equivalence assertion.  My clients will tell you my mantra that every word, sentence, and component of the 510(k) needs to be strategically written so as to specifically address the substantial equivalence statute and regulations.  Any information and data that doesn’t directly relate to this substantial equivalence exercise only convolutes the aim of the 510(k), and can easily confuse and frustrate the FDA reviewer.  This is because the inclusion of data not related to the substantial equivalence assertion signals to the FDA that the sponsor believes that those aspects are in fact germane to the substantial equivalence effort. In other words, that those attributes could significantly affect safety and effectiveness. Don’t lead FDA down that path unless it is truly necessary from the standpoint of the statutory intent of a section 510(k) notification.

If disclosing a non-triggering change(s) at all, then I prefer to put each change’s explanation in the subsection of the 510(k) corresponding to the nature of the particular non-triggering change.  For example, if a non-triggering change has been made in the labeling, then I disclose that in the labeling subsection.  If a non-triggering change was made regarding form/fit/function, then I disclose that in the device description (among other corresponding subsections as appropriate), and so on.

Transferring Foreign 510(k) “Ownership” to Domestic Subsidiary

In a nutshell, if a foreign sponsor/owner of a U.S. FDA 510(k) clearance wants to transfer/relinquish ownership and control over to its U.S. subsidiary (or any other party), then such a business/regulatory model can have regulatory merit and, if properly configured/managed, can generally work to meet FDA’s establishment registration and device listing requirements of 21 CFR Part 807.  Indeed, FDA’s establishment registration and device listing obligations are primarily driven by the operations in which a firm is engaged, and only secondarily (if at all, depending on the circumstances) by who obtained the 510(k) clearance.

It is true that FDA’s standard approach is to reflexively view the 510(k) owner as the owner/controller of the device specifications (i.e., as the Part 807 “manufacturer” or “specification developer”), and thus to view that firm as being ultimately responsible for assuring proper 21 CFR Part 820 GMP compliance and ongoing Part 807 compliance for the subject device.  Yet transfer of “ownership” / control of a 510(k) (and ultimate accountability for GMP) is a well-established business/regulatory scenario that FDA accepts as long as the proper notifications/adjustments are made to assure FDA knows who is the current/latest Part 807 “manufacturer”, “specification developer”, and “contract manufacturer”.

For example, a U.S. firm could, via the aforesaid FDA notifications/adjustments, take on the Part 807 role of being, as applicable, either the responsible “manufacturer” or “specification developer”, and can have the subject device fabricated outside the U.S. by a Part 807 “contract manufacturer” [such as the firm that originally sponsored/obtained the 510(k) clearance]. Moreover, if the finished devices in that scenario are imported into the U.S. by the U.S. firm and distributed from that same U.S. site into U.S. interstate commerce (whether directly to end users or to distributors), then the FDA told me that there would be no requirement for registration of an “initial importer” like there was previously when the foreign site was initially getting its products into the U.S. through a third-party importer/distributor.

Ultimately in such a scenario, don’t overlook the fact that the U.S. subsidiary site becomes the actual responsible “manufacturer” or “specification developer” who is held ultimately accountable for finished device design, fabrication, ongoing quality, etc., etc.  That means, for example, that FDA’s first (and typically only) direct focus for GMP inspections will be that U.S. subsidiary.  It also means that the U.S. site is ultimately responsible for critical regulatory events like recalls, 510(k) letters to file, and responding to inquiries from FDA’s adverse event monitoring group.